Decoding Biopharma in Day 1
The 4th Edition of the India Biopharma Leaders Conclave, scheduled for 13-14th June 2024, is set to explore “New Horizons in Biopharma, Biosimilars, & Biologics”. Day 1 will feature four insightful panel discussions delving into the current status and future prospects of Biosimilars, the need for R&D, regulatory guidelines, and the development of Cell & Gene therapy.
Additionally, two presentations will shed light on the advances in CAR-T Cell Therapy and strategies for efficient supply chain operations. This conclave promises to be a melting pot of ideas, innovations, and discussions shaping the future of Biopharma.
The first panel discussion at the 4th Edition: India Biopharma Leaders Conclave on 13th June, 2024, will delve into the intriguing world of Biosimilars, exploring their current status, future challenges, and opportunities. Key points of discussion include:
- Future of the Industry: What’s next for the biosimilar industry?
- Biosimilar Development: The rationale behind companies’ choice to develop specific biosimilars.
- Asset Selection: Factors influencing the selection of a biosimilar asset.
- Health Equity: How biosimilars have enhanced health equity and patient access to treatment.
- Market Decisions: Factors influencing manufacturers’ decisions to launch or withhold a biosimilar from the market.
- Next Wave: What lies ahead for the next generation of biosimilar products.
- Sustainability Strategies: Strategies for maintaining sustainability in biosimilars, both for new and existing products.
This discussion promises to offer valuable insights into the dynamic biosimilar landscape.
**
The second panel discussion will focus on the critical need for R&D in biosimilars as we enter a new phase of expansion. The discussion will cover:
- Demand Analysis: Examination of the current and future demand for biologics.
- Success Rates: A look at the success rates for developing new biosimilars.
- Global Impact: A global perspective on the impact of biosimilars.
- Industry Landscape: Monitoring the industry landscape and preparing for change.
- Interchangeability Studies: The importance and role of interchangeability studies in biosimilars.
- R&D Enhancement: Strengthening the foundations by enhancing the R&D operating model for biosimilars.
This panel is expected to shed light on the evolving landscape of biosimilar research and development, offering valuable insights for industry professionals and stakeholders.
The third panel discussion at the Conclave on day one, will provide an overview of the regulatory guidelines for biosimilars. The key points of discussion include:
- Recent Developments: An exploration of the recent developments in regulatory guidelines that impact the biosimilar industry.
- Approval Requirements: A deep dive into the regulatory requirements for the approval of biosimilars.
- Interchangeability: A discussion on the regulatory perspective on interchangeability and switching of biosimilars.
- Regulatory Compliance: An examination of clinical-phase-appropriate regulatory compliance in the development of biosimilars.
- Learning from FDA and EU: Insights into what can be learned from FDA and EU regulatory guidelines for application in our market.
The objective of the panel discussion is to offer a comprehensive understanding of the regulatory landscape for biosimilars, providing valuable insights for industry professionals navigating this complex field.
The fourth panel discussion at the 4th Edition: India Biopharma Leaders Conclave will delve into the exciting realm of Cell & Gene Therapy, discussing its present state and future prospects. The important points of discussion include:
- Therapy Landscape: An overview of the types of cell and gene therapies currently in development or on the market.
- Notable Advancements: Highlighting significant advancements and breakthroughs in the field.
- Development Hurdles: Discussion on the challenges faced in developing and manufacturing these therapies, including scalability, cost, and regulatory issues.
- Regulatory Standards: Ensuring that manufacturing processes meet regulatory standards for safety, efficacy, and consistency.
- Emerging Technologies: Exploration of emerging technologies and therapeutic modalities that could revolutionize the field, such as CRISPR-based gene editing and engineered cell therapies.
The outcome of the panel discussion may offer a comprehensive understanding of the dynamic landscape of cell and gene therapy, providing valuable insights for industry professionals and stakeholders.
Amidst the thought-provoking panel discussions, attendees will be enlightened by two comprehensive presentations shedding light on pivotal aspects of Biopharma.
Presentation 1:
Recent Advances & Future Prospective of CART T Cell Therapy
This presentation will provide an in-depth look at the recent advances and future prospects of CAR-T cell therapy. It will explain how engineered T cells recognize and attack cancer cells, and provide a visual representation of this interaction. The presentation will also cover FDA-approved CAR-T cell therapies and their target indications, such as CD19-targeted therapies for B-cell malignancies.
Furthermore, it will discuss the barriers to patient access to CAR-T cell therapies and efforts to overcome these, including considerations around reimbursement and healthcare policy. This presentation will be beneficial to the conclave attendees as it will provide them with a comprehensive understanding of the current state and future potential of CAR-T cell therapies.
Presentation 2:
Strategic Supply Chain for Efficient Operations
This presentation will focus on strategies for efficient supply chain operations. It will cover strategies for sourcing raw materials and components efficiently while maintaining quality and cost-effectiveness, techniques for optimizing inventory levels, and strategies for streamlining transportation, warehousing, and distribution processes.
The presentation will also highlight the importance of real-time visibility into the entire supply chain for proactive decision-making and risk management, and explore emerging trends and technologies shaping the future of supply chain management, such as artificial intelligence, autonomous vehicles, and 3D printing. This presentation will be beneficial to the conclave attendees as it will provide them with valuable insights into optimizing supply chain operations and staying ahead of emerging trends.
Thus, Day 1 of the 4th Edition of the India Biopharma Leaders Conclave promises a deep dive into Biopharma, with enlightening panel discussions and presentations, paving the way for future innovations in Biosimilars and CAR-T Cell Therapy.
–Rashmi Kumari
